{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T07:23:18Z","timestamp":1794813798449,"version":"4.9.1"},"reference-count":52,"publisher":"Informa UK Limited","issue":"11","license":[{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017876","name":"ADC Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017876","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012112","name":"Swedish Orphan Biovitrum AB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012112","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Declaration of Helsinki and Good Clinical Practice"},{"name":"Institutional Review Board or Independent Ethics Committee"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Leukemia &amp; Lymphoma"],"published-print":{"date-parts":[[2025,9,19]]},"DOI":"10.1080\/10428194.2025.2520440","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T19:02:31Z","timestamp":1751310151000},"page":"1990-2002","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["Loncastuximab tesirine in relapsed\/refractory diffuse large B-cell lymphoma: drug profile and expert opinion on the prevention and management of adverse events"],"prefix":"10.1080","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7154-8140","authenticated-orcid":false,"given":"Enrico","family":"Derenzini","sequence":"first","affiliation":[{"name":"Oncohematology Division, European Institute of Oncology IRCCS","place":["Milan, Italy"]},{"name":"Department of Health Sciences, University of Milan","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Gibb","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Christie NHS Foundation Trust","place":["Manchester, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Kwiatek","sequence":"additional","affiliation":[{"name":"Aidport - Clinical Trials Hospital","place":["Skorzewo, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7445-1459","authenticated-orcid":false,"given":"Paolo","family":"Strati","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma, The University of Texas, MD Anderson Cancer Center","place":["Houston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,6,30]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1975188"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2027612"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.27785"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.148809"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.5866"},{"key":"e_1_3_4_8_1","unstructured":"Roche\u2019s Polivy combination approved by European Commission for people with previously untreated diffuse large B-cell lymphoma. 2022 May 25. Roche Media & Investor Release."},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115304"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/20406207221103321"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21228553"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015789"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12237376"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2019.04.008"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.37349\/etat.2022.00112"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014663"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2022.100967"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00547-6"},{"key":"e_1_3_4_19_1","unstructured":"POLIVY (polatuzumab vedotin-piiq) FDA-approved prescribing information. Revised April 2023."},{"key":"e_1_3_4_20_1","unstructured":"POLIVY (polatuzumab vedotin) EMA summary of product characteristics. Revised March 2023."},{"key":"e_1_3_4_21_1","unstructured":"ZYNLONTA (loncastuximab tesirine-lpyl) FDA-approved prescribing information. Revised 2022."},{"key":"e_1_3_4_22_1","unstructured":"ZYNLONTA (loncastuximab tesirine) EMA summary of product characteristics. Revised; 2024."},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00139-X"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283459"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007512"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-10-813493"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-28533-4"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-023-00709-2"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-20-0351"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-20-0222"},{"key":"e_1_3_4_31_1","unstructured":"FDA grants accelerated approval to loncastuximab tesirine-lpyl for large B-cell lymphoma. 2021 April 23. FDA Resources for Information Approved Drugs."},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2021.1973998"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.09.001"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.284973"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-174257"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-174497"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.11.005"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002587"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.12.493"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.12.503"},{"key":"e_1_3_4_41_1","volume-title":"Paper presented at","author":"Pruett J","year":"2022","unstructured":"Pruett J, Zellner K, Kahl B, et\u00a0al. Characterization and management of cutaneous reactions in patients with relapsed or refractory diffuse large B-cell Lymphoma Treated With Loncastuximab Tesirine in the LOTIS-2 Trial. Paper presented at. Anaheim, CA, USA 47th Annual Oncology Nursing Society Congress; 2022."},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.285977"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2016.1175429"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.0208"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00103-4"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.02.009"},{"key":"e_1_3_4_47_1","unstructured":"CD19. CD19 molecule [Homo sapiens (human)]. 2024 September 17. Gene ID 930. NCBI Gene Database."},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(21)01899-1"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13221"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34816"},{"key":"e_1_3_4_51_1","unstructured":"ClinicalTrials.gov. A study to evaluate the safety and anti-cancer activity of Loncastuximab tesirine in combination with other anti-cancer agents in participants with relapsed or refractory B-cell Non-Hodgkin Lymphoma (LOTIS 7). Retrieved 30 May 2023 from https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04970901."},{"key":"e_1_3_4_52_1","unstructured":"ClinicalTrials Gov. Study to evaluate loncastuximab tesirine with Rituximab versus immunochemotherapy in participants with relapsed or refractory diffuse large B-cell lymphoma (LOTIS 5). Retrieved 17 April 2025 from https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04384484."},{"key":"e_1_3_4_53_1","unstructured":"ClinicalTrials Gov. A global study of novel agents in paediatric and adolescent relapsed and refractory B-cell non-Hodgkin lymphoma (Glo-BNHL). Retrieved 24 October 2024 from https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT05991388."}],"container-title":["Leukemia &amp; Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428194.2025.2520440","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T16:43:10Z","timestamp":1762188190000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10428194.2025.2520440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":52,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,9,19]]}},"alternative-id":["10.1080\/10428194.2025.2520440"],"URL":"https:\/\/doi.org\/10.1080\/10428194.2025.2520440","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"value":"1042-8194","type":"print"},{"value":"1029-2403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,30]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-04-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-10","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}